B-MICS better than C-SICS

Article

Biaxial microincision cataract surgery (B-MICS) is more successful than traditional cataract surgery in improving optical performance and reducing higher order aberrations, according to study results published in the December issue of the British Journal of Ophthalmology.

Biaxial microincision cataract surgery (B-MICS) is more successful than traditional cataract surgery in improving optical performance and reducing higher order aberrations, according to study results published in the December issue of the British Journal of Ophthalmology.

Professor PJ Pisella of the department of ophthalmology at the University Hospital of Bretonneau in Tours, France treated patients with bilateral cataract with B-MICS through a 1.7 mm clear corneal incision in one eye, and coaxial small-incision cataract surgery (C-SICS) through a 2.8 mm clear corneal incision in the opposite eye. All eyes were implanted with the Akreos MI60 AO intraocular lens (Bausch & Lomb), and the team compared corneal and ocular aberrations pre- and three-months postoperatively.

At the three-month follow-up point, eyes treated with B-MICS had lower values and reduced instances of trefoil, trefoil-like, higher-order aberrations, and corneal root mean square (RMS) when compared with C-SICS-treated eyes, although there were no differences between the two groups in terms of refraction, astigmatism and visual acuity values.

Thus the researchers concluded that B-MICS is a better surgical option than C-SICS for treating eyes with cataract, as it appears to reduce corneal aberrations and does not compromise postoperative optical performance.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.